Becton Dickinson reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% year-on-year, driven by strong performance in biologic drug delivery and advanced patient monitoring platforms.

Adjusted earnings per share (EPS) reached $3.23, a 4.9% increase from the prior year, exceeding internal expectations. The company raised the midpoint of its full-year adjusted EPS guidance to $12.62-$12.72 while maintaining revenue growth expectations toward the high end of the low single-digit range.

Segment Performance Highlights

Revenue growth was broad-based, with more than 90% of the portfolio delivering high single-digit growth. Key segments showed distinct momentum:

Strategic Priorities and Innovation

Management emphasized three strategic pillars: Compete, Innovate, and Deliver. Commercial execution improvements contributed to share gains, particularly in APM where incremental investments added 100-150 basis points to growth. Approximately 100 agreements have been signed across novel and biosimilar GLP-1 programs.

Innovation launches included the Liberty Tip stent graft for peripheral intervention and the Alira Thulium fiber laser system for endourology. These products target markets valued at approximately $2 billion and $1.5 billion respectively.

Financial Metrics and Guidance

Adjusted operating margin stood at 24.9%, down 130 basis points year-on-year, primarily due to tariff impacts of approximately 110 basis points. Adjusted gross margin was 54.3%, down 100 basis points. Year-to-date free cash flow increased 45% to $1.7 billion, reflecting improved working capital and lower non-operating cash items.

Net leverage ended the quarter at approximately 2.9 times, with management reaffirming a long-term target of 2.5 times. The company returned $3.1 billion to shareholders year-to-date, including $2.3 billion in share repurchases and $0.9 billion in dividends.

What the Numbers Show

A divergence exists between top-line acceleration and margin compression. While revenue grew 4.4%, adjusted operating margin contracted by 130 bps. This indicates that productivity gains from BD Excellence and favorable mix were insufficient to fully offset the ~110 bps tariff impact and continued investments in selling and R&D. However, the 45% surge in year-to-date free cash flow suggests that working capital efficiency is currently outpacing margin pressure, providing liquidity to support capital allocation targets despite the margin dip.

BD (NYSE: BDX) has deployed the BD Vmax 160, its next-generation pharmacy automation robot, at Fairview Health Services. This marks the first U.S. deployment of the system, designed to manage complex specialty therapies and refrigerated medications.

Fairview operates one of the nation’s largest health system pharmacy networks, filling an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services. The health system is investing in centralized operations to address growing demand for GLP-1s, biologics, and other specialty therapies that require different storage and fulfillment than traditional vials.

System Capabilities

The BD Vmax 160 is purpose-built for centralized fulfillment environments to automate labor-intensive workflows. Key features include:

• Automated inventory replenishment: Uses BD EasyLoad for overnight loading with a 3-second loading time per tote and 99.8% accuracy.
• Automated labeling: Meets requirements for all 50 states.
• Cold-chain capability: Designed for 2–8°C environments to support proper medication storage.
• Smart expiry detection: Flags expiration dates upon loading and blocks expired medications from dispensing.

Matt Sassone, President of BD Pharmacy Automation, stated that Fairview’s investment reflects a vision for scalable medication access models. The deployment builds on Fairview’s existing use of the BD Parata™ Max 2 high-speed vial filling robot.

What the Numbers Show

The precision metrics of the BD Vmax 160 highlight a shift toward high-volume automation in US pharmacies. With a 99.8% loading accuracy rate and a 3-second load time per tote, the system is engineered to handle the throughput required by large networks like Fairview, which processes 20,000 prescriptions weekly. This suggests that automation is becoming critical not just for speed, but for maintaining accuracy as prescription complexity increases with specialty drugs.

BD aims to connect these workflows through its Incada™ Connected Care Platform, moving toward more autonomous medication management across the care journey.